Cover Image

Plasma fibrinogen in essential hypertension patients

YOGESWARI .

Abstract


Plasma fibrinogen is an important component of the coagulation cascade and also a major determinant of blood viscosity and blood flow . Many factors including reduced blood flow due to elevated viscosity of plasma have been implicated in the pathogenesis of hypertension . The aim of this study is to assess the plasma fibrinogen level in hypertensives and to  compare whether there is difference in plasma fibrinogen level between obese and non-obese hypertensives and normal           individuals.Methods- This case control study was conducted in the Department of Internal Medicine,Rajiv Gandhi Government General Hospital, Institute of Biochemistry, Madras Medical College, Chennai. 30 cases of hypertension without obesity,30 cases of hypertension with obesity and 30 healthy controls were included in the study. Plasma fibrinogen level was measured by Clauss method.Results- Hypertensive patients was found to have elevated plasma fibrinogen levels than control subjects (1.83plus or minus 0.84gram per liter, p less than 0.016), among them Obese hypertensives had higher fibrinogen level (3.04plus or minus0.58gram per liter) than non obese hypertensives(2.70plus or minus0.40 gram per liter, p less than 0.001).           Conclusion-. Plasma fibrinogen level was higher in hypertensive patients than healthy controls. Thus monitoring of plasma            fibinogen level among hypertensives and using drugs to reduce to normal level may prevent the development of thrombotic  complications in hypertensive patients.


Full Text:

PDF

References


Doolittle RF, Spraggon G, Everse SJ. Three-dimensional structural studies on fragments of fibrinogen and fibrin. Curr Opin Struct Biol 1998; 8:792–8

Harkness J, Whittington RB. Blood plasma viscosity, an approximate temprature invariant arising from generalized concepts. Biorheology 1970;6:169-71.

Dormandy JA. Clinical importance of blood viscosity.Viscostas 1979;I:5-8

Zannad F, Voisin P, Brunnote F, Bruntz JF, Stoiz JF,Gilgenkrantz JM. Haemoreological abnormalities in arterial hypertension and their relation to cardiac hypertrophy. JHypertension 1988;6:293-7

Carretero OA, Oparil S (January 2000). Essential hypertension. Part I :definition and etiology 101 (3): 329–35. Retrieved 2009-06 -05.

Taj Muhammad Khan, Mumtaz Ali Marwat, Habibur Rehman COMPARISON OF PLASMA VISCOSITY AND FIBRINOGEN CONCENTRATION IN HYPERTENSIVE AND NORMOTENSIVE

DIABETICS Department of Physiology and Department of Medicine Saidu Medical College Swat, SMO, Health Department NWFP-2005;17(4)

Janus ED, for the Hong Kong Cardiovascular Risk Factor Prevalence Study Group. The Hong Kong Cardiovascular Risk Factor Prevalence Study 1995–1996. The University of Hong Kong: Hong Kong, 1997.

Kanda T, Takahashi T. Interleukin-6 and cardiovascular diseases. Jpn Heart J2004; 45: 183–193

Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol1999; 10: 435–441

James JS, Silbershatz H, Geoffrey H et al. Association of Fibrinogen with Cardiovascular Risk Factors andCardiovascular Diseae in the Framingham Offspring Population. Circulation 2000; 102:1634-8.

Chobanian AV, Bakris GL, Black HR, et al. (December 2003).”Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure “Hypertension 42 (6): 1206–52..

Herrick S,Blanc-Brude O,Gray A,Laurent G.Fibrinogen. Int J Biochem Cell Biol1999; 31:7416.

Haidaris PJ,Francis CW,Sporn LA,Arvan DS,Collichio FA,Marder VJ.Megakaryocyte and hepatocyte origins of human fibrinogen biosynthesis exhibit hepatocyte-specific expression of gamma chain variant polypeptides.Blood 1989;74:743-50.

S.Kamath,G.Y.H.Lip.Fibrinogen:biochemistry,epidemiology and

determinants,pathophysiology.QJM(2003)96(10):711 -729.doi:10.1093/qjmed/hcg129

Lee AJ, Lowe GD, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J. 1993; 69: 338–342.

Schneider DJ, Taatjes DJ, Howard DB, Sobel B E. Increasedreactivity of platelets induced by fibrinogen independent ofits binding to the IIb-IIIa surface glycoprotein: a potential contributor to cardiovascular risk. J Amer Coll Cardiol 1999;33: 261–6.

Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990; 227: 273–278.

Krobot K,Hense HW,Cremer P,Eberle E,Keilu.Determinants of plasma fibrinogen:relation to body weight,waist ti hip ratio, smoking,alcohol,age and sex.Results from the second MONICA 1989–1990. Arterioscler Thromb 1992; 12:780-84.

.Craveri A, Tornaghi G, Paganardi L, Ranieri R, Leonardi G, Di Bella M. Hemorrheologic disorders in obese patients. Study of the viscosity of the blood, erythrocytes, plasma, fibrinogen and the erythrocyte filtration index. Minerva Med1987; 78:899–906.

Lee AJ,Lowe GD,Woodward M,Tunstall-pedoe H.Fibrinogen in relation to personal history of prevalent hypertension,diabetes,stroke,intermittent claudication,coronary heart disease,and family history:the Scottish heart health study.Br Heart J 1993;69;338-342.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

An Initiative of The Tamil Nadu Dr M.G.R. Medical University